Lupin has completed the acquisition of VISUfarma B.V. from GHO Capital Partners LLP. This move supports Lupin’s plan to grow its specialty healthcare business and increase its presence in Europe.
With this acquisition, Lupin’s eye-care portfolio now includes more than 60 branded products. These cover areas such as:
This strengthens Lupin’s position in the growing global eye-care market.
VISUfarma brings an established business network across major European countries, including:
Its experienced team and strong relationships with healthcare professionals will help Lupin grow faster in these markets.
The demand for eye-care products is increasing due to:
The acquisition improves Lupin’s ability to meet this growing global demand.
Lupin is a global pharmaceutical company headquartered in Mumbai. Its products are sold in over 100 countries and include branded and generic medicines, biotechnology products, and APIs. The company operates 15 manufacturing sites and 7 research centres worldwide with more than 24,000 employees.
Also Read: March 2026 Auto Sales: Tata Motors Leads Growth, Mahindra Shows Stability Across Segments!
Lupin share price (NSE: LUPIN) was trading at ₹2,262.90 on April 2 at 1:50 pm, down ₹12 or 0.53% for the day. The stock opened at ₹2,269.20 and touched an intraday high of ₹2,269.20 and a low of ₹2,170.10. The company currently has a market capitalisation of about ₹1.03 lakh crore and trades at a P/E ratio of 20.83. Over the past year, the stock has moved between a 52-week high of ₹2,377.60 and a 52-week low of ₹1,795.20, while offering a dividend yield of 0.53% with a quarterly dividend of ₹3 per share.
The VISUfarma acquisition marks a key step in Lupin’s strategy to grow its specialty care business. The deal strengthens its ophthalmology portfolio and expands its footprint across Europe.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Apr 2, 2026, 1:55 PM IST
Kusum Kumari
Kusum Kumari is a Content Writer with 4 years of experience in simplifying financial market concepts. Currently crafting insightful content at Angel One, She specialise in breaking down complex topics into easy-to-understand pieces, blending expertise in market fundamentals and technical analysis.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN